Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands

Journal of Infectious Diseases

Volumn 187, Issue 4, 2003, Pages 640-649

  Mulvey, George L ^a   Marcato, Paola ^a   Kitov, Pavel I ^a   Sadowska, Joanna ^a   Bundle, David R ^a   Armstrong, Glen D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI VACCINE; SHIGA TOXIN; SHIGA TOXIN INHIBITOR DAISY; SHIGA TOXIN INHIBITOR STARFISH; SHIGA TOXIN RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FEMALE; HEMOLYTIC UREMIC SYNDROME; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; STRUCTURE ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ANTITOXINS; CARBOHYDRATE SEQUENCE; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; IMMUNOBLOTTING; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; OLIGOSACCHARIDES; SHIGA-LIKE TOXIN I; SHIGA-LIKE TOXIN II; STREPTOMYCIN; TREATMENT OUTCOME;

EID: 0037442497     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/373996     Document Type: Article

References (67)

1. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151:775-82.
2. Griffin PM, Ostroff SM, Tauxe RV, et al. Illnesses associated with Escherichia coli 0157:H7 infections: a broad clinical spectrum. Ann Intern Med 1988; 109:705-12.
3. Noel JM, Boedeker EC. Enterohemorrhagic Escherichia coli: a family of emerging pathogens. Dig Dis 1997; 15:67-91.
4. Carter AO, Borczyk AA, Carlson JA, et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987; 317:1496-500.
5. Goldwater PN, Bettelheim KA. Escherichia coli 'O' group serology of a haemolytic uraemic syndrome (HUS) epidemic. Scand J Infect Dis 2000; 32:385-94.
6. Besser RE, Griffin PM, Slutsker L. Escherichia coli O157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease. Annu Rev Med 1999; 50:355-67.
7. Banatvala N, Griffin PM, Greene KD, et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183:1063-70.
8. Fitzhenry RJ, Pickard DJ, Hartland EL, et al. Intimin type influences the site of human intestinal mucosal colonisation by enterohaemorrhagic Escherichia coli O157:H7. Gut 2002; 50:180-5.
9. Durno C, Soni R, Sherman P. Adherence of veto cytotoxin-producing Escherichia coli serotype O157:H7 to isolated epithelial cells and brush border membranes in vitro: role of type 1 fimbriae (pili) as a bacterial adhesin expressed by strain CL-49. Clin Invest Med 1989; 12:194-200.
10. Tatsuno I, Horie M, Abe H, et al. toxB gene on pO157 of enterohemorrhagic Escherichia coli O157:H7 is required for full epithelial cell adherence phenotype. Infect Immun 2001; 69:6660-9.
11. Tarr PI, Bilge SS, Vary JC Jr, et al. Iha: a novel Escherichia coli O157:H7 adherence-conferring molecule encoded on a recently acquired chromosomal island of conserved structure. Infect Immun 2000; 68:1400-7.
12. Donnenberg MS, Whittam TS. Pathogenesis and evolution of virulence in enteropathogenic and enterohemorrhagic Escherichia coli. J Clin Invest 2001; 107:539-48.
13. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11:142-201.
14. O'Brien AD, Holmes RK. Shiga and Shiga-like toxins. Microbiol Rev 1987; 51:206-20.
15. Schmidt H. Shiga-toxin-converting bacteriophages. Res Microbiol 2001; 152:687-95.
16. Karmali MA, Petric M, Louie S, Cheung R. Antigenic heterogeneity of Escherichia coli verotoxins. Lancet 1986; 1:164-5.
17. Hashimoto H, Mizukoshi K, Nishi M, et al. Epidemic of gastrointestinal tract infection including hemorrhagic colitis attributable to Shiga toxin 1-producing Escherichia coli O118:H2 at a junior high school in Japan. Pediatrics 1999; 103:E2.
18. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 1989; 160:994-8.
19. Scotland SM, Willshaw GA, Smith HR, Rowe B. Properties of strains of Escherichia coli O26:H11 in relation to their enteropathogenic or enterohemorrhagic classification. J Infect Dis 1990; 162:1069-74.
20. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 1999; 37:497-503.
21. Stein PE, Boodhoo A, Tyrrell GJ, Brunton JL, Read RJ. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature 1992; 355:748-50.
22. Fraser ME, Chernaia MM, Kozlov YV, James MN. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat Struct Biol 1994; 1:59-64.
23. 3. Biochemistry 1998; 37:1777-88.
24. Strockbine NA, Jackson MP, Sung LM, Holmes RK, O'Brien AD. Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1. J Bacteriol 1988; 170:1116-22.
25. Calderwood SB, Auclair F, Donohue-Rolfe A, Keusch GT, Mekalanos JJ. Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli. Proc Natl Acad Sci USA 1987; 84:4364-8.
26. Newland JW, Strockbine NA, Neill RJ. Cloning of genes for production of Escherichia coli Shiga-like toxin type II. Infect Immun 1987; 55:2675-80.
27. O'Brien AD, Tesh VL, Donohue-Rolfe A, et al. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 1992; 180:65-94.
28. Waddell T, Cohen A, Lingwood CA. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc Natl Acad Sci USA 1990; 87:7898-901.
29. DeGrandis S, Law H, Brunton J, Gyles C, Lingwood CA. Globotetraosylceramide is recognized by the pig edema disease toxin. J Biol Chem 1989; 264:12520-5.
30. Cohen A, Hannigan GE, Williams BR, Lingwood CA. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem 1987; 262:17088-91.
31. Keusch GT, Jacewicz M, Mobassaleh M, Donohue-Rolfe A. Shiga toxin: intestinal cell receptors and pathophysiology of enterotoxic effects. Rev Infect Dis 1991; 13(Suppl 4):S304-10.
32. Armstrong GD, Fodor E, Vanmaele R. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J Infect Dis 1991; 164:1160-7.
33. Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001; 69:6148-55.
34. Thorpe CM, Smith WE, Hurley BP, Acheson DW. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immun 2001; 69:6140-7.
35. Sjogren R, Neill R, Rachmilewitz D, et al. Role of Shiga-like toxin-I in bacterial enteritis - comparison between isogenic Escherichia coli strains induced in rabbits. Gastroenterology 1994; 106:306-17.
36. Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic-uremic syndrome. Semin Thromb Hemost 2001; 27:207-13.
37. Chalmers RM, Parry SM, Salmon RL, Smith RM, Willshaw GA, Cheasty T. The surveillance of vero cytotoxin-producing Escherichia coli O157 in Wales, 1990 to 1998. Emerg Infect Dis 1999; 5:566-9.
38. Cimolai N, Basalyga S, Mah DG, Morrison BJ, Carter JE. A continuing assessment of risk factors for the development of Escherichia coli 0157:H7-associated hemolytic uremic syndrome. Clin Nephrol 1994; 42:85-9.
39. Tesh VL, O'Brien AD. The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. Mol Microbiol 1991; 5:1817-22.
40. Louise CB, Obrig TG. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J Infect Dis 1995; 172:1397-401.
41. Lingwood CA. Verotoxin-binding in human renal sections. Nephron 1994; 66:21-8.
42. Kitov PI, Sadowska JM, Mulvey G, et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000; 403:669-72.
43. Nishikawa K, Matsuoka K, Kita E, et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc Natl Acad Sci USA 2002; 99:7669-74.
44. Marcato P, Mulvey G, Read RJ, Vander HK, Nation PN, Armstrong GD. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect Dis 2001; 183:435-43.
45. Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 2000; 6:265-70.
46. Suzaki Y, Ami Y, Nagata N, et al. Protection of monkeys against Shiga toxin induced by Shiga toxin-liposome conjugates. Int Arch Allergy Immunol 2002; 127:294-8.
47. Mukherjee J, Chios K, Fishwild D, et al. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun 2002; 70:612-9.
48. Karmali MA. The nature of immunity to the Escherichia coli Shiga toxins (verocytotoxins) and options for toxoid immunization. Jpn J Med Sci Biol 1998; 51(Suppl):S26-35.
49. Armstrong GD, Rowe PC, Goodyer P, et al. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis 1995; 171:1042-5.
50. Armstrong GD, McLaine PN, Rowe PC. Clinical trials of Synsorb-Pk in preventing hemolytic-uremic syndrome. In: Kaper JB, O'Brien AD, eds. Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. Washington, DC: American Society for Microbiology, 1998:374-84.
51. Kokai-Kun JF, Melton-Celsa AR, O'Brien AD. Elastase in intestinal mucus enhances the cytotoxicity of Shiga toxin type 2d. J Biol Chem 2000; 275:3713-21.
52. Ito H, Terai A, Kurazono H, Takeda Y, Nishibuchi M. Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome. Microb Pathog 1990; 8:47-60.
53. Kitov PI, Paszkiewicz E, Wakarchuk WW, Bundle DR. Preparative scale chemo-enzymatic synthesis of the large carbohydrate assemblies using α(1-4)-galactosyltransferase/UDP-4′-Gal-epimerase fusion protein. Met Enzymol (in press).
54. Kitov PI, Bundle DR. Synthesis and structure-activity relationships of di- and trisaccharide inhibitors for Shiga-like toxin type 1. J Chem Soc Perkin Trans 1 2001;838-53.
55. Head SC, Karmali MA, Lingwood CA. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits: evidence for B subunit modulation of a subunit function. J Biol Chem 1991; 266:3617-21.
56. Armstrong GD, Peppler MS. Maintenance of biological activity of pertussis toxin radioiodinated while bound to fetuin-agarose. Infect Immun 1987; 55:1294-9.
57. Wadolkowski EA, Burris JA, O'Brien AD. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 1990; 58:2438-45.
58. Paton JC, Paton AW. Survival rate of mice after transient colonization with Escherichia coli clones carrying variant Shiga-like toxin type II operons. Microb Pathog 1996; 20:377-83.
59. Bast DJ, Brunton JL, Karmali MA, Richardson SE. Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits. Infect Immun 1997; 65:2019-28.
60. Lindgren SW, Samuel JE, Schmitt CK, O'Brien AD. The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality. Infect Immun 1994; 62:623-31.
61. Boyd B, Tyrrell G, Maloney M, Gyles C, Brunton J, Lingwood C. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targeting and results in a verotoxin 1-like disease in pigs. J Exp Med 1993; 177:1745-53.
62. Bielaszewska M, Clarke I, Karmali MA, Petric M. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect Immun 1997; 65:2509-16.
63. Lee YC. Binding modes of mammalian hepatic Gal/GalNAc receptors. Ciba Found Symp 1989; 145:80-93.
64. Isogai E, Isogai H, Hayashi S, et al. Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection. Microbiol Immunol 2000; 44:89-95.
65. Yoh M, Frimpong EK, Voravuthikunchai SP, Honda T. Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. Can J Microbiol 1999; 45:732-9.
66. Grif K, Dierich MP, Karch H, Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998; 17:761-6.
67. Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 1992; 20:25-9.